Regal Investment Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Regal Investment Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,243	Closed	-$605K	–	497
2024 Q4	$605K	Sell	7,243 -89	-1%	-$7.31K	0.05%	293
2024 Q3	$536K	Sell	7,332 -67	-0.9%	-$5.04K	0.04%	341
2024 Q2	$507K	Sell	7,399 -131	-2%	-$9.09K	0.03%	359
2024 Q1	$521K	Sell	7,530 -6,971	-48%	-$479K	0.04%	354
2023 Q4	$1.04M	Buy	14,501 +891	+7%	+$51.3K	0.08%	222
2023 Q3	$709K	Buy	13,610 +186	+1%	+$10.8K	0.06%	243
2023 Q2	$850K	Buy	13,424 +3,789	+39%	+$236K	0.07%	218
2023 Q1	$522K	Buy	+9,635	New	+$466K	0.05%	281

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Regal Investment Advisors's ITCI Position: Q1 2025 in Review

Regal Investment Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 7,243 shares — an estimated $605K sold.

Regal Investment Advisors first reported a position in ITCI in Q1 2023 and held it in 8 quarters. The position peaked at $1.04M in Q4 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Regal Investment Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Regal Investment Advisors sold 7,243 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $605K.
Regal Investment Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2023 and held it in 8 quarters.
Regal Investment Advisors's Intra-Cellular Therapies Inc. position peaked at $1.04M in Q4 2023.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Regal Investment Advisors's 13F filing for Q1 2025, filed 12 May 2025.